British Patient Capital makes commitment to the Dementia Discovery Fund 2

The commercial subsidiary of the British Business Bank has invested in SV Health Investors’ fund to invest in therapeutics to treat dementia. 

British Patient Capital, a commercial subsidiary of the British Business Bank, has made a £25 million commitment to the Dementia Discovery Fund 2 (DDF-2) which is managed by global private equity and venture capital investment platform SV Health Investors.

The investment follows British Patient Capital’s £24 million investment in the first Dementia Discovery Fund.

Including British Patient Capital’s commitment to DDF-2, the fund has now achieved its target raise of $250 million (£193.6 million).

The Dementia Discovery Fund (DDF) is a specialised venture capital fund that invests exclusively in companies developing or enabling novel therapeutics for dementia. 

Leveraging a team of experienced investment professionals, global access to top academic centres and industry strategic partners, DDF has extensive expertise in the dementia space. 

Since 2015, DDF has held a portfolio of 19 companies, leading to 11 assets in the clinic, significant follow-on investment and a number of strategic pharma partnerships.